CSPC Innovation Pharmaceutical Co Ltd SZSE:300765:
SAYS CO SUBMITS LISTING APPLICATION TO HONG KONG STOCK EXCHANGE
CSPC Innovation Submits Listing Application To Hong Kong Stock Exchange
CSPC Innovation Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from CSPC Innovation Pharmaceutical
- CSPC Innovation Pharmaceutical: Revenue up 7.71% but net loss deepens; biopharma focus strengthened by Jushi stake buy
- CSPC Innovation Pharmaceutical Plans To Seek Hong Kong Listing
- CSPC Innovation Pharmaceutical: Revenue up, but net loss driven by R&D surge; biopharma growth and global deals highlight H1
- CSPC Innovation Pharmaceutical: Revenue fell and losses widened in Q1 2025 amid R&D surge and raw material price drops
- CSPC Innovation Pharmaceutical: Net profit plunged 87.63% as R&D spending rose and caffeine prices dropped, but biopharma sales soared 153%
Later from CSPC Innovation Pharmaceutical
- CSPC Innovation Pharmaceutical: Revenue rose but higher R&D and lower margins led to a net loss; biopharma growth was strong
- CSPC Innovation Pharmaceutical: Q1 revenue up 40.82% year-over-year, but net loss widened on higher R&D and FX losses
Follow CSPC Innovation Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Innovation Pharmaceutical